Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
1-Minute Consult

Is the MTHFR gene mutation associated with thrombosis?

Andrew Dhawan, MD, DPhil and Charis Eng, MD, PhD
Cleveland Clinic Journal of Medicine November 2023, 90 (11) 661-663; DOI: https://doi.org/10.3949/ccjm.90a.23044
Andrew Dhawan
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; Center for Personalized Genetic Healthcare, Medical Specialties Institute, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
Charis Eng
Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; Center for Personalized Genetic Healthcare, Medical Specialties Institute, Cleveland Clinic, Cleveland, OH; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH; Professor of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Find this author on Cleveland Clinic
  • Article
  • Info & Metrics
  • PDF
Loading

Polymorphisms of the methylene tetrahydrofolate reductase (MTHFR) gene are common among the general population, and data from large meta-analyses do not support the association of these variants with elevated prothrombotic risk. Clinicians should educate patients with MTHFR polymorphisms about the lack of evidence for association with thrombotic risk and focus on addressing modifiable thrombotic risk factors.

BACKGROUND

MTHFR is an essential enzyme that is encoded by the MTHFR gene, which catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the primary form of folate in circulation. This substance, 5-methyltetrahydrofolate, is also a necessary cofactor for the conversion of homocysteine to methionine, required for protein synthesis.1 Reduced expression of MTHFR has been implicated in elevated serum homocysteine and reduced serum folate levels, a condition known as hyperhomocysteinemia.2–4 The relationship between serum homocysteine levels and disease has been investigated across several disease states. In this review, we focus on its putative relationship with venous thromboembolism (VTE).

WHAT IS A SINGLE NUCLEOTIDE POLYMORPHISM?

Single nucleotide polymorphisms (SNPs) and single nucleotide variants (SNVs) both refer to single base-pair changes in the nucleic acid sequence of a gene, but they are not interchangeable terms. SNVs are changes that occur in less than 1% of the population, whereas SNPs occur in at least 1% of the population.5 Neither of these terms implies pathogenicity of the genetic change, and both may be coloquially referred to as “mutations.” It should also be noted that databases cataloging human genetic variation are biased towards populations with Northern European heritage. Patients with African, South American, Indigenous, Pacific Islander, and Southeast Asian heritage are underrepresented, complicating the estimation of true population prevalence for a given genetic variant.

HOW COMMON IN THE GENERAL POPULATION?

From an epidemiologic perspective—because SNPs in MTHFR are common, some occurring in up to 40% of the general population—achieving statistical significance for an association between SNPs and a clinical variable of interest is subject to many potential biases.6 It is important for the clinician to recognize potential sources of confounding in these studies.

First, not all MTHFR SNPs are equivalent, and different SNPs should be considered independently as risk factors, as should homozygosity and heterozygosity. Second, correlation does not imply causation, and epidemiologic studies can provide correlative evidence, but confounding effects and a biological basis for the association must also be carefully examined.

Crucially, dietary intake of B vitamins influences the measurement of homocysteine, and dietary differences must therefore be considered when comparing populations with MTHFR variants.1 Lastly, both selection bias for patients who have been tested for MTHFR variants and ascertainment bias in retrospective cohorts may play a large role in influencing study results.

RISK OF THROMBOSIS AND MTHFR VARIANTS

The most common MTHFR SNPs in the general population are the C677T (rs1801133) and A1298C variants (rs1801131), thought to affect the thermostability of the methylenetetrahydrofolate reductase.6 The C677T allele has been better studied, and its combined heterozygous and homozygous incidence varies from 20% to 30% in East Asian people to 20% to 40% in White and Hispanic populations in the United States.7 The A1298C variant is less well-studied, and its allele frequency is estimated at 10% to 30% in White populations and 20% to 40% in Southeast Asian populations (combined heterozygous and homozygous incidence).8 This variant is thought to be milder and less clinically significant.6

As mentioned, while these SNPs are associated with reduced methylenetetrahydrofolate reductase enzyme activity and increased homocysteine levels, the relationship between these findings and thrombotic risk has been controversial. Of note, homocysteine levels are impacted by many factors, including concomitant renal disease, thyroid disease, nutritional deficiencies, and alcohol intake.1,9

Early analyses of whether homocysteine levels are associated with VTE came from a 1997 meta-analysis that pooled results of 9 studies and showed an increased risk of VTE in the setting of hyperhomocysteinemia.10 A larger-scale meta-analysis comprising 11,000 cases and 21,000 controls from 31 databases was published in 2013. It showed that there was no evidence for an association with homozygotes for the MTHFR C677T variant and VTE, but due to incomplete data, was unable to examine for an association between homocysteine, MTHFR variant, and VTE.11

Likewise, a review of 9 case-control studies involving 382 patients found insufficient evidence to support any association between the MTHFR C677T variant and cerebral venous sinus thrombosis.12 A meta-analysis of 26 studies examining the role of the MTHFR C677T variant and recurrent unexplained pregnancy loss showed an association only in 5 studies from China and no association in European studies.13 The authors concluded that at most, the presence of this SNP is a risk factor for recurrent unexplained pregnancy loss in Chinese patients, but not European patients.13

SHOULD PATIENTS BE TESTED FOR MTHFR VARIANTS?

Given the tenuous associations identified in the literature associating MTHFR variants with VTE, we do not advocate for the routine testing of patients for MTHFR variants. This approach is supported by the American College of Medical Genetics and Genomics.14

TEST INTERPRETATION

If a patient has had a prior genetic test with a result reported for MTHFR, the clinician must carefully consider whether the reported genetic change (whether it is an SNV, SNP, or more complex alteration) is known to be pathogenic and is consistent with the patient’s presentation. In cases where the identified genetic change is a common SNP, we do not recommend any further workup or management based on the prior genetic testing. In situations with rarer variants or complex genomic rearrangements identified, consultation with a genetic counselor may be helpful.

MANAGEMENT

The propensity to clot is influenced by a myriad of factors in each patient, and a patient’s MTHFR status is a single, likely noncontributory component of this risk. In patients with VTE, the management of a patient with an MTHFR variant should be no different than the standard of care. In those who are at risk of thrombosis, it is essential to recognize that the common MTHFR SNPs are not thought to be contributory to VTE risk. Other risk factors such as age, family history, and medical comorbidities such as diabetes and hypertension are greater determinants of VTE risk. We recommend that all patients maintain a healthy weight, stop smoking, limit alcohol consumption, and exercise regularly. Dietary modifications, such as including folate-rich foods like leafy greens, legumes, and fortified cereals, may also be beneficial.

THE BOTTOM LINE

The relationship between MTHFR variants and thrombosis risk is a complex, multifactorial issue. Early studies reported a potential association between common SNPs in MTHFR and VTE, but later, larger meta-analyses have refuted these results. At this time, based on the best available evidence, there is no support for the association of the most common MTHFR SNPs with significantly elevated thrombotic risk. We recommend that clinicians focus on modifiable risk factors of thrombosis, such as weight management, smoking cessation, and underlying medical issues.

DISCLOSURES

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

Acknowledgments

Andrew Dhawan, MD, DPhil, is the recipient of a PTEN Research Foundation Young Investigator Award and an American Academy of Neurology Scholar Award. Charis Eng, MD, PhD, is the Sondra J. and Stephen R. Hardis Endowed Chair of Cancer Genomic Medicine and a Lerner Eminent Scholar at the Cleveland Clinic.

  • Copyright © 2023 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Selhub J
    . Homocysteine metabolism. Annu Rev Nutr 1999; 19:217–246. doi:10.1146/annurev.nutr.19.1.217
    OpenUrlCrossRefPubMed
  2. ↵
    1. Frosst P,
    2. Blom HJ,
    3. Milos R, et al
    . A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10(1):111–113. doi:10.1038/ng0595-111
    OpenUrlCrossRefPubMed
    1. Weisberg I,
    2. Tran P,
    3. Christensen B,
    4. Sibani S,
    5. Rozen R
    . A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64(3):169–172. doi:10.1006/mgme.1998.2714
    OpenUrlCrossRefPubMed
  3. ↵
    1. Govindaiah V,
    2. Naushad SM,
    3. Prabhakara K,
    4. Krishna PC,
    5. Radha Rama Devi A
    . Association of parental hyperhomocysteinemia and C677T methylene tetrahydrofolate reductase (MTHFR) polymorphism with recurrent pregnancy loss. Clin Biochem 2009; 42(4–5):380–386. doi:10.1016/j.clinbiochem.2008.12.003
    OpenUrlCrossRefPubMed
  4. ↵
    1. Firth HV,
    2. Hurst A
    . Oxford Desk Reference: Clinical Genetics and Genomics. 2nd ed. Oxford, United Kingdom: Oxford University Press; 2017.
  5. ↵
    1. Moll S,
    2. Varga EA
    . Homocysteine and MTHFR mutations. Circulation 2015; 132(1):e6–e9. doi:10.1161/CIRCULATIONAHA.114.013311
    OpenUrlFREE Full Text
  6. ↵
    1. Wang X,
    2. Fu J,
    3. Li Q,
    4. Zeng D
    . Geographical and ethnic distributions of the MTHFR C677T, A1298C, and MTRR A66G gene polymorphisms in Chinese populations: a meta-analysis. PLoS one 2016; 11(4):e0152414. doi:10.1371/journal.pone.0152414
    OpenUrlCrossRefPubMed
  7. ↵
    1. Sherry ST,
    2. Ward MH,
    3. Kholodov M, et al
    . dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29(1):308–311. doi:10.1093/nar/29.1.308
    OpenUrlCrossRefPubMed
  8. ↵
    1. Zhang Y,
    2. Wang Q,
    3. Li Q,
    4. Lu P
    . Association between hyperhomocysteinemia and thyroid hormones in euthyroid diabetic subjects. BioMed Research International 2015; 2015. doi:10.1155/2015/196379
    OpenUrlCrossRef
  9. ↵
    1. Ray JG
    . Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158(19):2101–2106. doi:10.1001/archinte.158.19.2101
    OpenUrlCrossRefPubMed
  10. ↵
    1. Simone B,
    2. De Stefano V,
    3. Leoncini E, et al
    . Risk of venous thromboembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol 2013; 28(8):621–647. doi:10.1007/s10654-013-9825-8
    OpenUrlCrossRefPubMed
  11. ↵
    1. Gouveia LO,
    2. Canhão P
    . MTHFR and the risk for cerebral venous thrombosis—a meta-analysis. Thromb Res 2010; 125(4):e153–e158. doi:10.1016/j.thromres.2009.10.019
    OpenUrlCrossRefPubMed
  12. ↵
    1. Ren A,
    2. Wang J
    . Methylenetetrahydrofolate reductase C677T polymorphism and the risk of unexplained recurrent pregnancy loss: a meta-analysis. Fertil Steril 2006; 86(6):1716–1722. doi:10.1016/j.fertnstert.2006.05.052
    OpenUrlCrossRefPubMed
  13. ↵
    1. Hickey SE,
    2. Curry CJ,
    3. Toriello HV
    . ACMG practice guideline: lack of evidence for MTHFR polymorphism testing [published correction appears in Genet Med 2020]. Genet Med 2013; 15(2):153–156. doi:10.1038/gim.2012.165
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 90 (11)
Cleveland Clinic Journal of Medicine
Vol. 90, Issue 11
1 Nov 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Is the MTHFR gene mutation associated with thrombosis?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Is the MTHFR gene mutation associated with thrombosis?
Andrew Dhawan, Charis Eng
Cleveland Clinic Journal of Medicine Nov 2023, 90 (11) 661-663; DOI: 10.3949/ccjm.90a.23044

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Is the MTHFR gene mutation associated with thrombosis?
Andrew Dhawan, Charis Eng
Cleveland Clinic Journal of Medicine Nov 2023, 90 (11) 661-663; DOI: 10.3949/ccjm.90a.23044
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • BACKGROUND
    • WHAT IS A SINGLE NUCLEOTIDE POLYMORPHISM?
    • HOW COMMON IN THE GENERAL POPULATION?
    • RISK OF THROMBOSIS AND MTHFR VARIANTS
    • SHOULD PATIENTS BE TESTED FOR MTHFR VARIANTS?
    • TEST INTERPRETATION
    • MANAGEMENT
    • THE BOTTOM LINE
    • DISCLOSURES
    • Acknowledgments
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

1-Minute Consult

  • What diagnostic tests should be done after discovering clubbing in a patient without cardiopulmonary symptoms?
  • Does my adult patient need a measles vaccine?
  • Do I need to treat supine hypertension in my hospitalized patient?
Show more 1-Minute Consult

Vascular-Medicine

  • Anchors away
  • Should you use compression duplex ultrasonography to detect deep vein thrombosis to evaluate unexplained fevers?
Show more Vascular-Medicine

Hematology

  • Anchors away
  • Should you use compression duplex ultrasonography to detect deep vein thrombosis to evaluate unexplained fevers?
  • Is the MTHFR gene mutation associated with thrombosis?
Show more Hematology

Genetics

  • Anchors away
Show more Genetics

Similar Articles

Subjects

  • Genetics
  • Hematology
  • Vascular Medicine

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire